title: The role of the angiotensin AT2 receptor on the diurnal variations of nociception and motor coordination in rats.
abstract: Phasic pain demonstrates significant diurnal variation in rats. Angiotensin II modulates pain transmission and the diurnal variation in nociception in several rodent pain models. The participation of AT2 receptors in the diurnal regulation of nociception is not yet elucidated. In the present study we investigated the effects of selective peptide AT2 agonist CGP 42112A and the nonpeptide AT2 receptor antagonist PD 123319 on the nociception, motor coordination and arterial blood pressure. Male Wistar 12 weeks old rats were used. CGP 42112A was injected at single doses of 1 and 5 μg/rat intracerebroventricularly (ICV) and infused chronically ICV at a dose of 12 μg/rat/day during 14 days by osmotic minipumps. PD123319 was injected at single doses of 1 and 5 μg/rat, ICV and chronically subcutaneously at a dose of 10 mg/kg/day/14 days. Nociception was assessed by an analgesimeter, arterial blood pressure (ABP) was measured by tail cuff method, and motor coordination by Rota-rod method. Single doses of CGP 42112A (1 and 5 μg/rat) provoked a short lasting antinociception. Unlike acute injection, chronic CGP 42112A infusion increased nociception at the beginning and the end of light phase thus attenuating the diurnal variations observed in the controls. Moreover, it produced an increase of ABP and improved motor coordination. Both acute (1 μg/rat) and chronic PD 123319 treatment resulted in a decrease of pain threshold and chronic treatment attenuated its diurnal fluctuation. Our data support a role for Ang II type 2 receptors in the control of diurnal variations of nociception in rats.
authors.affiliation: Institute of Neurobiology, Bulgarian Academy of Sciences, Medical University, Sofia, Bulgaria. pechlivanova@yahoo.com
authors.forename: D M
authors.initials: DM
authors.lastname: Pechlivanova
authors.forename: P P
authors.initials: PP
authors.lastname: Markova
authors.forename: D
authors.initials: D
authors.lastname: Popov
authors.forename: A G
authors.initials: AG
authors.lastname: Stoynev
mesh_terms: D057912:Angiotensin II Type 2 Receptor Blockers / Q000008:administration & dosage / Q000494:pharmacology*; D000818:Animals; D001794:Blood Pressure / Q000187:drug effects; D002940:Circadian Rhythm / Q000187:drug effects; D004305:Dose-Response Relationship, Drug; D007093:Imidazoles / Q000008:administration & dosage / Q000494:pharmacology*; D057967:Infusions, Intraventricular; D055104:Infusions, Subcutaneous; D008297:Male; D009043:Motor Activity / Q000187:drug effects*; D059225:Nociception / Q000187:drug effects*; D009842:Oligopeptides / Q000008:administration & dosage / Q000494:pharmacology*; D011725:Pyridines / Q000008:administration & dosage / Q000494:pharmacology*; D051381:Rats; D017208:Rats, Wistar; D044139:Receptor, Angiotensin, Type 2 / Q000819:agonists / Q000502:physiology*; D045442:Rotarod Performance Test
chemical_list: D057912:Angiotensin II Type 2 Receptor Blockers; D007093:Imidazoles; D009842:Oligopeptides; D011725:Pyridines; D044139:Receptor, Angiotensin, Type 2; C060894:CGP 42112A; C073402:PD 123319